Saisheng Pharmaceutical: Announcement on the 2025 Profit Distribution Plan
Securities code: 300485 Securities abbreviation: Saisheng Pharmaceutical Announcement number: 2026-011 Beijing Saisheng Pharmaceutical Co., Ltd.
Announcement on the 2025 Profit Distribution Plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Review procedure
On March 29, 2026, the company held the 13th meeting of the fifth board of directors, reviewed and approved the "Proposal on the Company's 2025 Profit Distribution Plan", and agreed to submit the proposal to the company's 2025 annual shareholders' meeting for review and implementation after approval.
2. Basic situation of profit distribution
As audited and confirmed by Grant Thornton Certified Public Accountants (Special General Partnership), the company's 2025 consolidated statement showed that the net profit attributable to shareholders of the listed company was 14,570,990.82 yuan, and the parent company's 2025 net profit was 48,201,296.27 yuan. In accordance with the provisions of the "Company Law" and the "Articles of Association", when the accumulated statutory surplus reserve reaches more than 50% of the registered capital, it can no longer be withdrawn. Therefore, no statutory surplus reserve has been withdrawn this year. As of December 31, 2025, the company's consolidated undistributed profits were 1,797,951,199.89 yuan, and the parent company's accumulated undistributed profits were 1,932,657,897.54 yuan.
In accordance with the relevant provisions of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" and the "Articles of Association", combined with the actual needs of the company's development, and on the premise of complying with the principle of profit distribution, ensuring the company's normal operations and long-term development, and taking into account the immediate and long-term interests of shareholders, the company has drafted a profit distribution plan for 2025 as follows: The company will use 481,666,400 shares as the base and pay 10 to all shareholders for every A cash dividend of RMB 0.3 (tax included) was distributed for each share, with a total dividend distribution of RMB 14,449,992.00.
If the company's share capital changes due to the exercise of equity incentive grants, listing of new shares, share repurchase, etc., resulting in the company's total share capital being reduced by the number of shares in the repurchase account, the distribution ratio will be adjusted based on the principle that the total distribution amount remains unchanged. The remaining undistributed profits are carried forward and distributed in subsequent years.
3. Details of cash dividend plan
(1) Whether other risk warning situations may be involved
1． When a listed company discloses its annual cash dividend plan (including non-dividend distribution), it shall list the following indicators:
Item Current year Previous year Previous year
Total cash dividends (yuan) 14,449,992 0 10,596,660.80 Total repurchase and cancellation (yuan) 0 0 0 Attributable to shareholders of listed companies
14,570,990.82 -68,853,096.03 102,917,838.16 Net profit (yuan)
R&D investment (yuan) 143,712,013.23 129,951,530.32 102,630,567.50 Operating income (yuan) 404,718,439.82 416,481,789.63 476,569,581.71 Consolidated statements accumulated at the end of the year
1,797,951,199.89 Undistributed profits (yuan)
Parent company's financial statements for the current year
1,932,657,897.54 undistributed profits (yuan)
Whether the listing has been completed for three complete meetings
Yes □No
Calculation year
The cumulative total of the last three fiscal years
25,046,652.80 Total cash dividends (yuan)
The cumulative total of the last three fiscal years
Total amount of repurchase and cancellation (yuan)
The average of the last three fiscal years
16,211,910.9833 Net profit (yuan)
The cumulative total of the last three fiscal years
The total amount of cash dividends and repurchase cancellation is 25,046,652.8 yuan (yuan)
The cumulative total of the last three fiscal years
376,294,111.05 Total R&D investment (yuan)
The cumulative total of the last three fiscal years
Total R&D investment accounts for 29% of cumulative operating revenue (%)
Whether it touches "GEM Stocks"
Rule 9.4 of the Listing Rules □Yes No
Those specified in item (8) may be
Implement other risk warning situations
Other notes:
The company's net profit in the most recent fiscal year was positive, and the undistributed profits at the end of the consolidated statement and the parent company's statement were both positive. The company's cumulative cash dividends in the last three fiscal years are higher than 30% of the average annual net profit in the last three fiscal years. Therefore, it does not trigger other risk warning situations that may be implemented as stipulated in Article 9.4 (8) of the "Shenzhen Stock Exchange GEM Stock Listing Rules".
(2) Reasonable explanation of cash dividend plan
The company's profit distribution plan for 2025 complies with the China Securities Regulatory Commission's "Notice on Further Implementing Matters Related to Cash Dividends by Listed Companies", "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends by Listed Companies" and other laws and regulations, normative documents, and the "Articles of Association". It is in line with the company's profit distribution policy and shareholder dividend return plan, is conducive to all shareholders sharing the company's operating results, and is legal and compliant.
4. Documents for reference
Resolution of the 13th meeting of the fifth board of directors.
Announcement is hereby made.
Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd.
March 31, 2026